Sponsored

Building Diagnostic Stewardship into Sepsis Management

Advertisement

Sepsis management is a consistent burden on U.S. health systems, accounting for 2.5 million hospital stays and over $41 billion in annual healthcare costs.1,2 As hospitals increasingly face growing capacity constraints, tight operational margins, and shifting reimbursement models for sepsis care, health systems are under pressure to adjust and find new approaches to familiar problems. This environment creates an opportunity to evolve clinical and operational decision making into a comprehensive strategy that bridges the gaps between bedside decisions, antibiotic optimization, and hospital performance. By building a robust diagnostic stewardship model, health systems can support clinical decision-making while meeting critical quality benchmarks.

The Strategic Value of a Comprehensive Diagnostic Portfolio

Antimicrobial resistance continues to pose a severe global health threat. Traditional stewardship models often focus on pharmacy-driven interventions that regulate when antibiotics should be used, manage treatment duration, and limit use for non-bacterial etiologies. Stewardship can be particularly complex within the context of sepsis, where urgency often demands rapid decision making. A recent hospital-onset sepsis study showed that approximately 20% of suspected critical infection events stem from non-infectious causes, demonstrating the value of timely diagnostics to help avoid days of unnecessary broad-spectrum antibiotics.3,4

To complement these traditional pharmacy-driven models, progressive healthcare leadership means recognizing that diagnostic stewardship is a vital component of therapeutic decision making. This alignment can enhance sepsis care and support optimal antimicrobial usage at every stage of the patient journey. Because complex syndromes like sepsis present differently in every patient, a single test rarely tells the whole story. Instead, a multi-marker diagnostic approach offers complementary clinical insight. Perfusion and severity indicators, such as serum lactate testing, provide rapid baseline results sometimes essential for immediate resuscitation and satisfying quality compliance. Serial testing of host-response and inflammatory markers, including procalcitonin (PCT), C-reactive protein (CRP), and interleukin-6 (IL-6), offers visibility into the patient’s immune response aiding clinicians in evaluating disease trajectory and guiding antibiotic deescalation alongside clinical acumen. 

Effective diagnostic stewardship leverages integrated workflows across the entire patient continuum, from emergency department triage to discharge. Across this care pathway high-quality point-of-care testing can help guide immediate bedside evaluation while early use of rapid blood cultures helps satisfy critical timelines during sepsis management, such as those dictated by the SEP-1 bundle. Additionally, automated high-throughput laboratory platforms allow for more comprehensive and continuous monitoring. Establishing targeted and proactive testing protocols helps care teams identify deteriorating patients earlier, build a cohesive diagnostic approach, and aids in distinguishing true bacterial infections from non-infectious systemic inflammation. Ultimately, tailored diagnostic strategies account for the heterogeneous nature of syndromes, helping clinicians navigate complex presentation variations and personalize care for every patient.

Diagnostic Stewardship as an Operational Strategy

Programs like the CMS’s Hospital Value-Based Purchasing (VBP) Program directly tie hospital reimbursement to time-sensitive diagnostic and treatment bundles for sepsis care.5 Meeting these strict windows requires rapid, reliable diagnostic throughput. However, healthcare leaders increasingly recognize that bundle compliance alone is not enough. Regulatory bodies like CMS and CDC are expanding focus toward hospital-wide sepsis outcomes and mortality benchmarks. Focusing too narrowly on bundle compliance risks missing broader opportunities for operational efficiency and patient safety throughout hospitalization.

Some clinical societies recommend an expanded diagnostic approach to support hospital systems and clinical evaluation. The Association for Diagnostics and Laboratory Medicine (ADLM) recommends leveraging biomarkers like PCT to safely guide antibiotic discontinuation.6 Similarly, the Society of Critical Care Medicine (SCCM) and the Infectious Diseases Society of America (IDSA) suggest measuring PCT alongside clinical evaluation for new fever in adult ICU, if there is no clear focus of infection.7 Aligning with these recommendations and national initiatives, such as the CDC’s Hospital Sepsis Program Core Elements, helps organizations strengthen key operational metrics while building a more holistic and structured approach.8 In doing so health systems can see improvements in:

  • Time-to-Treatment and Mortality – In cases of severe septic shock, studies show mortality can increase by as much as ~8% for each hour effective antimicrobial therapy is delayed.9 Establishing standardized workflows and rapid diagnostic pathways helps care teams rapidly identify septic shock, implement targeted therapy, and reduce diagnostic uncertainty for non-shock presentations.
  • Length of Stay– Dynamic monitoring through biomarkers, blood gas analysis, and rapid blood cultures provides clinicians with the objective confidence needed to safely de-escalate therapy, reduce level of care (ICU vs floor), and support appropriate discharge. More robust diagnostic monitoring may also potentially mitigate readmission rates associated with complex conditions such as sepsis.
  • Cost and Quality Alignment– Health system data demonstrates that a 30% reduction in antibiotic use results in a 40% decrease in hospital-onset Clostridioides difficile (C. diff) infections.10 Implementing diagnostic stewardship upfront limits broad-spectrum antibiotic overuse, protects native flora, and may help prevent costly downstream complications.

Actionable Frameworks for Health Systems

To successfully implement diagnostic stewardship and drive toward operational efficiency, systems should consider several strategy frameworks:

  • Multidisciplinary Governance– Establish joint diagnostic and antimicrobial stewardship committees that connect stakeholders across pharmacy, emergency department, intensive care units, and laboratory medicine.
  • EHR-Integrated Workflow Support- Embed standardized diagnostic order sets and automated de-escalation protocols or flagged communication pop ups directly into Electronic Health Records (EHR) workflows and pair with active multidisciplinary support
  • Outcome-Oriented Metric Tracking– Evaluate success across both clinical and operational metrics moving beyond initial bundle compliance to measure antibiotic therapy length, ICU length of stay, 30-day readmissions, and overall sepsis mortality

Health systems that proactively adopt a diagnostic stewardship approach to these challenges will help strengthen both clinical outcomes and long-term financial resilience. Integrating a comprehensive, multi-platform diagnostic menu into daily clinical workflow empowers healthcare teams to meet quality metrics, while optimizing antimicrobial exposure and delivering high-quality, life-saving care in every setting for every patient. Diagnostic stewardship represents the next evolution for healthcare organizations committed to continuously optimizing clinical and quality performance.

References

  1. AHRQ Issues Report to Congress on Burden of Sepsis in U.S. Hospital Care. Accessed October 8, 2026. https://www.ahrq.gov/news/newsroom/press-releases/sepsis-report-to-congress.html
  2. McDermott KW. Most Frequent Principal Diagnoses for Inpatient Stays in U.S. Hospitals, 2018. July 2021. Accessed October 8, 2026. https://hcup-us.ahrq.gov/reports/statbriefs/sb277-Top-Reasons-Hospital-Stays-2018.jsp
  3. Manzoor F, Klompas M, Seetharaman S, Chan C, Rhee C. Underlying Causes and Preventability of Hospital-Onset Sepsis Events. JAMA Network Open. 2026;9(9):e2634324. doi:10.1001/jamanetworkopen.2026.34324
  4. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. doi:10.1016/S1473-3099(17)30592-3
  5. The Hospital Value-Based Purchasing (VBP) Program. Accessed October 8, 2026. https://www.cms.gov/medicare/quality/value-based-programs/hospital-purchasing
  6. AACC Guidance Document on The Clinical Use of Procalcitonin. Accessed October 9, 2026. https://myadlm.org/science-and-research/academy-guidance/clinical-use-of-procalcitonin
  7. SCCM and IDSA Guidelines for Evaluating New Fever in Adult Patients in the ICU. Accessed October 9, 2026. https://www.sccm.org/clinical-resources/guidelines/guidelines/guidelines-for-evaluating-new-fever-adult-icu
  8. Hospital Sepsis Program Core Elements. Accessed October 8, 2026. https://www.cdc.gov/sepsis/hcp/core-elements/index.html
  9. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596. doi:10.1097/01.CCM.0000217961.75225.E9
  10. Kazakova SV, Baggs J, Yi SH, et al. Associations of facility-level antibiotic use and hospital-onset Clostridioides difficile infection in US acute-care hospitals, 2012–2018. Infection Control & Hospital Epidemiology. 2021;43(8):1067-1069. doi:10.1017/ice.2021.151
Advertisement

Next Up in Public Health

Advertisement